Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Eastern Road, Zhengzhou 450052, Henan, China.
Biomater Sci. 2019 Jun 25;7(7):2640-2651. doi: 10.1039/c9bm00214f.
The combination of gene therapy and immunotherapy has the potential to systemically promote anti-tumor effects while reducing adverse reactions. Small interfering RNA (siRNA) has generated great interest in biology, engineering and medicine, especially for cancer treatment due to its ability to knock down genes of interest. Nanomaterials play significant roles in the design of delivery systems of siRNA, and nanomaterial-mediated siRNA delivery in cancer immunotherapy is one of the most important directions for future clinical cancer treatment. Here, we review the recent advances in nanomaterial mediated targeted delivery of siRNA to dendritic cells (DCs), tumor-associated macrophages (TAMs), immune checkpoint inhibitors, B lymphocytes, natural killer cells (NKs), and immunosuppressive cytokines. Fundamental challenges in nucleic acid delivery enabled by bio-barriers, its promising solution strategies and future directions are also reviewed.
基因治疗和免疫治疗的结合具有系统性地增强抗肿瘤效果、降低不良反应的潜力。小干扰 RNA(siRNA)在生物学、工程学和医学领域引起了极大的兴趣,特别是在癌症治疗方面,因为它能够敲低感兴趣的基因。纳米材料在 siRNA 递释系统的设计中发挥着重要作用,而纳米材料介导的 siRNA 递释在癌症免疫治疗中是未来临床癌症治疗的最重要方向之一。在这里,我们综述了纳米材料介导的 siRNA 靶向递送至树突状细胞(DC)、肿瘤相关巨噬细胞(TAMs)、免疫检查点抑制剂、B 淋巴细胞、自然杀伤细胞(NK)和免疫抑制细胞因子的最新进展。我们还综述了生物屏障促进核酸递释的基本挑战、有前景的解决方案策略以及未来的方向。